RBC Capital analyst Sean Dodge maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and maintains the target price at $270.
According to TipRanks data, the analyst has a success rate of 42.0% and a total average return of -6.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
A modest outperformance in Q3 was driven by stronger than anticipated results in TAS, yet this was overshadowed by challenges in R&DS, which are expected to persist over the next year. This includes a significant single project cancellation and the postponement of two major trials until 2025. Despite recent setbacks, the risk/reward is still seen as favorable after the stock's recent decline.
The company indicated that the market remains relatively stable, although issues with bookings are arising from delays and drug failures, as opposed to a significant effect from pipeline rationalization, according to an analyst's research note.
The company has encountered a challenging industry operating environment. Commentary from the company implies that pharma portfolio realignments related to IRA may be concluding, and it seems the company is poised to benefit from the pharmaceutical industry's trend of vendor consolidation.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇资本市场分析师Sean Dodge维持$艾昆纬 (IQV.US)$买入评级，维持目标价270美元。
根据TipRanks数据显示，该分析师近一年总胜率为42.0%，总平均回报率为-6.2%。
此外，综合报道，$艾昆纬 (IQV.US)$近期主要分析师观点如下：
第三季度表现略好于预期，主要受TAS的业绩强劲推动，但这被研发部门面临的挑战所掩盖，预计未来一年将持续存在。这包括一个重大单项目取消以及将两项重要试验推迟至2025年。尽管最近遇到挫折，但股价最近下跌后，风险/回报仍被认为是有利的。
公司表示市场仍然相对稳定，尽管预订方面出现问题，原因是延迟和药物失败，而不是管道合理化的显着影响，这是根据分析师的研究报告。
公司遇到了具有挑战性的行业经营环境。公司的评论暗示与IRA相关的药品组合重组可能即将结束，似乎公司准备从药品行业的供应商整合趋势中受益。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
